The impact of proteomics in the understanding of the molecular basis of paclitaxel-resistance in ovarian tumors

Current Cancer Drug Targets

Volumn 12, Issue 8, 2012, Pages 987-997

  Vergara, D ^a,b   Tinelli, A ^c   Iannone, A ^d   Maffia, M ^a,b  

^a UNIVERSITY OF SALENTO   (Italy)

^b ASL Lecce   (Italy)

^c VITO FAZZI HOSPITAL   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Anticancer drugs; Mass spectrometry; Ovarian cancer; Paclitaxel; Proteomics; Two dimensional electrophoresis

Indexed keywords

CARBOPLATIN; CISPLATIN; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL;

CANCER CHEMOTHERAPY; CYTOREDUCTIVE SURGERY; INDUCTION CHEMOTHERAPY; INTRACELLULAR SIGNALING; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; OVARY CANCER; PROTEOMICS; REVIEW;

DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; PROTEOMICS; TUBULIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84867793823     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912803251171     Document Type: Review

References (87)

1. Jemal, A.; Bray, F.; Center, M. M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011, 61(2), 69-90.
2. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2012. CA Cancer J. Clin. 2012, 62 (1), 10-29.
3. Yap, T. A.; Carden, C. P.; Kaye, S. B. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat. Rev. Cancer 2009, 9 (3), 167-181.
4. Langdon, S. P.; Smyth, J. F. Hormone therapy for epithelial ovarian cancer. Curr. Opin. Oncol. 2008, 20 (5), 548-553.
5. Monga, M.; Carmichael, J.A.; Shelley, W. E.; Kirk, M. E.; Krepart, G. V.; Jeffrey, J. F.; Pater, J. L. Surgery without adjuvant chemotherapy for early epithelial ovarian carcinoma after comprehensive surgical staging. Gynecol. Oncol. 1991, 43 (3), 195-197.
6. Armstrong, D. K.; Bundy, B.; Wenzel, L.; Huang, H. Q.; Baergen, R.; Lele, S.; Copeland, L. J.; Walker, J. L.; Burger RA; Gynecologic Oncology Group, Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 2006, 354 (1), 34-43.
7. Alberts, D. S.; Liu, P. Y.; Hannigan, E. V.; O'Toole, R.; Williams, S. D.; Young, J. A.; Franklin, E. W.; Clarke-Pearson, D. L.; Malviya, V. K.; DuBeshter, B. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 1996, 335 (26), 1950-1955.
8. McGuire, W. P.; Hoskins, W. J.; Brady, M. F.; Kucera, P. R.; Partridge, E. E.; Look, K. Y.; Clarke-Pearson, D. L.; Davidson, M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 1996, 334 (1), 1-6.
9. Piccart, M. J.; Bertelsen, K.; James, K.; Cassidy, J.; Mangioni, C.; Simonsen, E.; Stuart, G.; Kaye, S.; Vergote, I.; Blom, R.; Grimshaw, R.; Atkinson, R. J.; Swenerton, K. D.; Trope, C.; Nardi, M.; Kaern, J.; Tumolo, S.; Timmers, P.; Roy, J. A.; Lhoas, F.; Lindvall, B.; Bacon, M.; Birt, A.; Andersen, J. E.; Zee, B.; Paul, J.; Baron, B.; Pecorelli, S. Randomized intergroup trial of cisplatinpaclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl. Cancer Inst. 2000, 92 (9), 699-708.
10. Ozols, R. F.; Bundy, B. N.; Greer, B. E.; Fowler, J. M.; Clarke-Pearson, D.; Burger, R. A.; Mannel, R. S.; DeGeest, K.; Hartenbach, E. M.; Baergen R. Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecological Oncology Group Study. J. Clin. Oncol. 2003, 21 (17), 3194-3200.
11. du Bois, A.; Neijt, J. P.; Thigpen, J. T. First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer: a new standard of care? Ann. Oncol. 1999, 10 (1), 35-41.
12. Neijt, J. P.; Engelholm, S. A.; Tuxen, M. K.; Sorensen, P. G.; Hansen, M.; Sessa, C.; de Swart, C. A.; Hirsch, F. R.; Lund, B.; van Houwelingen, H. C. Exploratory Phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J. Clin. Oncol. 2000, 18 (17), 3084-3092.
13. Bookman, M. A. First-line chemotherapy in epithelial ovarian cancer. Clin. Obstet. Gynecol. 2012, 55 (1), 96-113.
14. van der Burg, M. E.; van Lent, M.; Buyse, M.; Kobierska, A.; Colombo, N.; Favalli, G.; Lacave, A. J.; Nardi, M.; Renard, J.; Pecorelli, S. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N. Engl. J. Med. 1995, 332 (10), 629-634.
15. Vergote, I.; Tropé, C. G.; Amant, F.; Kristensen, G. B.; Ehlen, T.; Johnson, N.; Verheijen, R. H.; van der Burg, M. E.; Lacave, A. J.; Panici, P. B.; Kenter, G. G.; Casado, A.; Mendiola, C.; Coens, C.; Verleye, L.; Stuart, G. C.; Pecorelli, S.; Reed, N. S. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med. 2010, 363 (10), 943-953.
16. Agarwal R.; Kaye, S. B. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer 2003, 3 (7), 502-516.
17. Vasey, P. A. Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies. Br. J. Cancer 2003, 89 (3), S23-S28.
18. Etienne-Manneville, S. From signaling pathways to microtubule dynamics: the key players. Curr. Opin. Cell. Biol. 2010, 22 (1), 104-111.
19. Moss, D. K.; Lane, J. D. Microtubules: forgotten players in the apoptotic execution phase. Trends Cell. Biol. 2006, 16 (7), 330-338.
20. Jordan M. A.; Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 2004, 4 (4), 253-265.
21. Wani, M. C.; Taylor, H. L.; Wall, M. E.; Coggon, P.; McPhail, A. T. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 1971, 93 (9), 2325-2327.
22. Sandor, V.; Fojo, T.; Bates, S. E. Future perspectives for the development of P-glycoprotein modulators. Drug Resist. Updat. 1998, 1 (3), 190-200.
23. Kavallaris, M. Microtubules and resistance to tubulin-binding agents. Nat. Rev. Cancer 2010, 10 (3), 194-204.
24. Szajnik, M.; Szczepanski, M. J.; Czystowska, M.; Elishaev, E.; Mandapathil, M.; Nowak-Markwitz, E.; Spaczynski, M.; Whiteside, T. L. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene 2009, 28 (49), 4353-4363.
25. Kelly, M. G.; Alvero, A. B.; Chen, R.; Silasi, D. A.; Abrahams, V. M.; Chan, S.; Visintin, I.; Rutherford, T.; Mor, G. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 2006, 66 (7), 3859-3868.
26. Wang, A. C.; Su, Q. B.; Wu, F. X.; Zhang, X. L.; Liu, P. S. Role of TLR4 for paclitaxel chemotherapy in human epithelial ovarian cancer cells. Eur. J. Clin. Invest. 2009, 39 (2), 157-164.
27. Huang, L.; Ao, Q.; Zhang, Q.; Yang, X.; Xing, H.; Li, F.; Chen, G.; Zhou, J.; Wang, S.; Xu, G.; Meng, L.; Lu, Y.; Ma, D. Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1alpha. J. Cancer Res. Clin. Oncol. 2010, 136 (3), 447-456.
28. Fu, Y.; Hu, D.; Qiu, J.; Xie, X.; Ye, F.; Lu, W. G. Overexpression of glycogen synthase kinase-3 in ovarian carcinoma cells with acquired paclitaxel resistance. Int. J. Gynecol. Cancer 2011, 21 (3), 439-44.
29. Kawai, T.; Akira, S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010, 11 (5), 373-384.
30. Shah, M. A.; Schwartz, G. K. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin. Cancer Res. 2001, 7 (8), 2168-2181.
31. Di Michele, M.; Della Corte, A.; Cicchillitti, L.; Del Boccio, P.; Urbani, A.; Ferlini, C.; Scambia, G.; Donati, M. B.; Rotilio, D. A proteomic approach to paclitaxel chemoresistance in ovarian cancer cell lines. Biochim. Biophys. Acta 2009, 1794 (2), 225-236.
32. Cicchillitti, L.; Michele, M.; Urbani, A.; Ferlini, C.; Donati, M. B.; Scambia, G.; Rotilio, D. Comparative proteomic analysis of paclitaxel sensitive A2780 epithelial ovarian cancer cell line and its resistant counterpart A2780TC1 by 2D-DIGE: the role of ERp57. J. Proteome Res. 2009, 8 (4), 1902-1912.
33. Frickel, E. M.; Frei, P.; Bouvier, M.; Stafford, W. F.; Helenius, A.; Glockshuber, R.; Ellgaard, L. ERp57 is a multifunctional thioldisulfide oxidoreductase. J. Biol. Chem. 2004, 279 (18), 18277-18287.
34. Turano, C.; Coppari, S.; Altieri, F.; Ferraro, A. Proteins of the PDI family: unpredicted non-ER locations and functions. J. Cell. Physiol. 2002, 193 (2), 154-163.
35. Ludueña, R. F. Multiple forms of tubulin: different gene products and covalent modifications. Int. Rev. Cytol. 1998, 178, 207-275.
36. Orr, G. A.; Verdier-Pinard, P.; McDaid, H.; Horwitz, S. B. Mechanisms of Taxol resistance related to microtubules. Oncogene 2003, 22 (47), 7280-7295.
37. Kavallaris, M.; Kuo, D. Y.; Burkhart, C. A.; Regl, D. L.; Norris, M. D.; Haber, M.; Horwitz, S. B. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J. Clin. Invest. 1997, 100 (5), 1282-1293.
38. Kavallaris, M.; Burkhart, C. A.; Horwitz, S. B. Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol. Br. J. Cancer 1999, 80 (7), 1020-1025.
39. Ferrandina, G.; Zannoni, G. F.; Martinelli, E.; Paglia, A.; Gallotta, V.; Mozzetti, S.; Scambia, G.; Ferlini, C. Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin. Cancer Res. 2006, 12 (9), 2774-2779.
40. Verdier-Pinard, P.; Shahabi, S.; Wang, F.; Burd, B.; Xiao, H.; Goldberg, G. L.; Orr, G. A.; Horwitz, S. B. Detection of human betaV-tubulin expression in epithelial cancer cell lines by tubulin proteomics. Biochemistry 2005, 44 (48), 15858-15870.
41. Bhattacharya R.; Cabral. F. A ubiquitous beta-tubulin disrupts microtubule assembly and inhibits cell proliferation. Mol. Biol. Cell. 2004, 15 (7), 3123-3131.
42. Cicchillitti, L.; Penci, R.; Di Michele, M.; Filippetti, F.; Rotilio, D.; Donati, M. B.; Scambia, G.; Ferlini, C. Proteomic characterization of cytoskeletal and mitochondrial class III beta-tubulin. Mol. Cancer Ther. 2008, 7 (7), 2070-2079.
43. De Donato, M.; Mariani, M.; Petrella, L.; Martinelli, E.; Zannoni, G. F.; Vellone, V.; Ferrandina, G.; Shahabi, S.; Scambia, G.; Ferlini, C. Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer. J. Cell. Physiol. 2012, 227 (3), 1034-1041.
44. Amaravadi, R.; Thompson, C. B. The survival kinases Akt and Pim as potential pharmacological targets. J. Clin. Invest. 2005, 115 (10), 2618-2624.
45. Xie, Y.; Burcu, M.; Linn, D. E.; Qiu, Y.; Baer, M. R. Pim-1 kinase protects P-glycoprotein from degradation and enables its glycosylation and cell surface expression. Mol. Pharmacol. 2010, 78 (2), 310-318.
46. Lee, D. H.; Chung, K.; Song, J. A.; Kim, T. H.; Kang, H.; Huh, J. H.; Jung, S. G.; Ko, J. J.; An, H. J. Proteomic identification of paclitaxel-resistance associated hnRNP A2 and GDI 2 proteins in human ovarian cancer cells. J. Proteome Res. 2010, 9 (11), 5668-5676.
47. Apweiler, R.; Hermjakob, H.; Sharon, N. On the frequency of protein glycosylation, as deduced from analysis of the SWISSPROT database. Biochim. Biophys. Acta 1999, 1473 (1), 4-8.
48. Williams, T. I.; Toups, K. L.; Saggese, D. A.; Kalli, K. R.; Cliby, W. A.; Muddiman, D. C. Epithelial ovarian cancer: disease etiology, treatment, detection, and investigational gene, metabolite, and protein biomarkers. J. Proteome Res. 2007, 6 (8), 2936-2962.
49. Pan, S.; Chen, R.; Aebersold, R.; Brentnall, T. A. Mass spectrometry based glycoproteomics-from a proteomics perspective. Mol. Cell. Proteomics 2011, 10 (1), R110.003251.
50. Di Michele, M.; Marcone, S.; Cicchillitti, L.; Della Corte, A.; Ferlini, C.; Scambia, G.; Donati, M. B.; Rotilio D. Glycoproteomics of paclitaxel resistance in human epithelial ovarian cancer cell lines: towards the identification of putative biomarkers. J. Proteomics 2010, 73 (5), 879-898.
51. Nakayama, K.; Nakayama, N.; Davidson, B.; Katabuchi, H.; Kurman, R. J.; Velculescu, V. E.; Shih, Ie. M.; Wang, T. L. Homozygous deletion of MKK4 in ovarian serous carcinoma. Cancer Biol. Ther. 2006, 5 (6), 630-634.
52. Nakayama, K.; Nakayama, N.; Davidson, B.; Sheu, J. J.; Jinawath, N.; Santillan, A.; Salani, R.; Bristow, R. E.; Morin, P. J.; Kurman, R. J.; Wang, T. L.; Shih, Ie. M. A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proc. Natl. Acad. Sci. U. S. A. 2006, 103 (49), 18739-18744.
53. Jinawath, N.; Vasoontara, C.; Yap, K. L.; Thiaville, M. M.; Nakayama, K.; Wang, T. L.; Shih, I. M. NAC-1, a potential stem cell pluripotency factor, contributes to paclitaxel resistance in ovarian cancer through inactivating Gadd45 pathway. Oncogene 2009, 28 (18), 1941-1948.
54. Ueda, S. M.; Yap, K. L.; Davidson, B.; Tian, Y.; Murthy, V.; Wang, T. L.; Visvanathan, K.; Kuhajda, F. P.; Bristow, R. E.; Zhang H, H.; Shih, Ie. M. Expression of fatty acid synthase depends on NAC1 and is associated with recurrent ovarian serous carcinomas. J. Oncol. 2010, 2010, 285191.
55. Tian, Y.; Tan, A. C.; Sun, X.; Olson, M. T.; Xie, Z.; Jinawath, N.; Chan, D. W.; Shih, I. M.; Zhang, Z.; Zhang, H. Quantitative proteomic analysis of ovarian cancer cells identified mitochondrial proteins associated with paclitaxel resistance. Proteomics Clin. Appl. 2009, 3 (11), 1288-1295.
56. Ross, P. L.; Huang, Y. N.; Marchese, J. N.; Williamson, B.; Parker, K.; Hattan, S.; Khainovski, N.; Pillai, S.; Dey, S.; Daniels, S.; Purkayastha, S.; Juhasz, P.; Martin, S.; Bartlet-Jones, M.; He, F.; Jacobson, A.; Pappin, D. J. Multiplex protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagent. Mol. Cell. Proteomics 2004, 3 (12), 1154-1169.
57. Carré, M.; André, N.; Carles, G.; Borghi, H.; Brichese, L.; Briand, C.; Braguer, D. Tubulin is an inherent component of mitochondrial membranes that interacts with the voltage-dependent anion channel. J. Biol. Chem. 2002, 277 (37), 33664-33669.
58. Varbiro, G.; Veres, B.; Gallyas, F Jr.; Sumegi, B. Direct effect of Taxol on free radical formation and mitochondrial permeability transition. Free Radic. Biol. Med. 2001, 31 (4), 548-558.
59. Kidd, J. F.; Pilkington, M. F.; Schell, M. J.; Fogarty, K. E.; Skepper, J. N.; Taylor, C. W.; Thorn, P. Paclitaxel affects cytosolic calcium signals by opening the mitochondrial permeability transition pore. J. Biol. Chem. 2002, 277 (8), 6504-6510.
60. André, N.; Braguer, D.; Brasseur, G.; Gonçalves, A.; Lemesle-Meunier, D.; Guise, S.; Jordan, M. A.; Briand, C. Paclitaxel induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells. Cancer Res. 2000, 60 (19), 5349-5353.
61. Shimizu, S.; Narita, M.; Tsujimoto, Y. Bcl-2 family of proteins target mitochondrial channel VDAC to regulate apoptogenic cytochrome c release. Nature 1999, 399 (6735), 483-487.
62. Shimizu, S.; Matsuoka, Y.; Shinohara, Y.; Yoneda, Y.; Tsujimoto, Y. Essential role of voltage-dependent anion channel in various forms of apoptosis in mammalian cells. J. Cell. Biol. 2001, 152 (2), 237-250.
63. Leonard, G. D.; Polgar, O.; Bates, S. E. ABC transporters and inhibitors: new targets, new agents. Curr. Opin. Investig. Drugs 2002, 3 (11), 1652-1659.
64. Yakirevich, E.; Sabo, E.; Naroditsky, I.; Sova, Y.; Lavie, O.; Resnick, M. B. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas. Gynecol. Oncol. 2006, 100 (1), 152-159.
65. Surowiak, P.; Materna, V.; Denkert, C.; Kaplenko, I.; Spaczyński, M.; Dietel, M.; Zabel, M.; Lage, H. Significance of cyclooxygenase 2 and MDR1/P-glycoprotein coexpression in ovarian cancers. Cancer Lett. 2006, 235 (2), 272-280.
66. van der Zee, A. G.; Hollema, H.; Suurmeijer, A. J.; Krans, M.; Sluiter, W. J.; Willemse, P. H.; Aalders, J. G.; de Vries, E. G. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J. Clin. Oncol. 1995, 13 (1), 70-78.
67. Vergara, D.; Bellomo, C.; Zhang, X.; Vergaro, V.; Tinelli, A.; Lorusso, V.; Rinaldi, R.; Lvov, Y. M.; Leporatti, S.; Maffia M. Lapatinib/Paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer. Nanomedicine 2011, 16. [Epub ahead of print].
68. Krishna, R.; Mayer, L. D. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 2000, 11 (4), 265-283.
69. Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; Gray-Goodrich, M.; Campbell, H.; Mayo, J.; Boyd, M. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 1991, 83 (11), 757-766.
70. Schenone, S.; Tintori, C.; Botta, M. Using insights into Pim1 structure to design new anticancer drugs. Curr. Pharm. Des. 2010, 16 (35), 3964-3978.
71. Walther, T. C.; Mann, M. Mass spectrometry-based proteomics in cell biology. J. Cell. Biol. 2010, 190 (4), 491-500.
72. Rifai, N.; Gillette, M. A.; Carr, S. A. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 2006, 24 (8), 971-983.
73. Wang, P.; Whiteaker, J. R.; Paulovich A. G. The evolving of mass spectrometry in cancer biomarker discovery. Cancer Biol. Ther. 2009, 8 (12), 1083-1094.
74. Yang, X.; Lazar I. M. MRM screening/biomarker discovery with linear ion trap MS: a library of human cancer-specific peptides. BMC Cancer 2009, 9, 96.
75. Gerber, S. A.; Rush, J.; Stemman, O.; Kirschner, M. W.; Gygi, S. P. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc. Natl. Acad. Sci. USA. 2003, 100 (12), 6940-6945.
76. Solyanik, G. I. Multifactorial nature of tumor drug resistance. Exp. Oncol. 2010, 32 (3), 181-185.
77. Vaughan, S.; Coward, J. I.; Bast, R. C. Jr.; Berchuck, A.; Berek, J. S.; Brenton, J. D.; Coukos, G.; Crum, C. C.; Drapkin, R.; Etemadmoghadam, D.; Friedlander, M.; Gabra, H.; Kaye, S. B.; Lord, C. J.; Lengyel, E.; Levine, D. A.; McNeish, I. A.; Menon, U.; Mills, G. B.; Nephew, K. P.; Oza, A. M.; Sood, A. K.; Stronach, E. A.; Walczak, H.; Bowtell, D. D.; Balkwill, F. R. Rethinking ovarian cancer: recommendations for improving outcomes. Nat. Rev. Cancer 2011, 11 (10), 719-725
78. Emmert-Buck, M. R.; Bonner, R. F.; Smith, P. D.; Chuaqui, R. F.; Zhuang, Z.; Goldstein, S. R.; Weiss, R. A.; Liotta, L. A. Laser capture microdissection. Science 1996, 274 (5289), 998-1001.
79. Umar, A.; Kang, H.; Timmermans, A. M.; Look, M. P.; Meijer-van Gelder, M. E.; den Bakker, M. A.; Jaitly, N.; Martens, J. W.; Luider, T. M.; Foekens, J. A.; Pasa-Tolić, L. Identification of a putative protein profile associated with tamoxifen therapy resistance in breast cancer. Mol. Cell. Proteomics 2009, 8 (6), 1278-1294.
80. Caprioli, R. M.; Farmer, T. B.; Gile, J. Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS. Anal. Chem. 1997, 69 (23), 4751-4760.
81. Franck, J.; Arafah, K.; Elayed, M.; Bonnel, D.; Vergara, D.; Jacquet, A.; Vinatier, D.; Wisztorski, M.; Day, R.; Fournier, I.; Salzet, M. MALDI imaging mass spectrometry: state of the art technology in clinical proteomics. Mol. Cell. Proteomics 2009, 8 (9), 2023-2033.
82. El Ayed, M.; Bonnel, D.; Longuespée, R.; Castelier, C.; Franck, J.; Vergara, D.; Desmons, A.; Tasiemski, A.; Kenani, A.; Vinatier, D.; Day, R.; Fournier, I.; Salzet, M. MALDI imaging mass spectrometry in ovarian cancer for tracking, identifying, and validating biomarkers. Med. Sci. Monit. 2010, 16 (8), 233-245.
83. Lemaire, R.; Desmons, A.; Tabet, J. C.; Day, R.; Salzet, M.; Fournier, I. Direct analysis and MALDI imaging of formalin-fixed, paraffin-embedded tissue sections. J. Proteome Res. 2007, 6 (4), 1295-1305.
84. Saldanha, S. N.; Tollefsbol, T. O. The role of nutraceuticals in chemoprevention and chemotherapy and their clinical outcomes. J. Oncol. 2012, 2010, 192464.
85. Yunos, N.M.; Beale, P.; Yu, J. Q.; Huq, F. Synergism from the combination of oxaliplatin with selected phytochemicals in human ovarian cancer cell lines. Anticancer Res. 2011, 31 (12), 4283-4289.
86. Vergara, D.; Valente, C. M.; Tinelli, A.; Siciliano, C.; Lorusso, V.; Acierno, R.; Giovinazzo, G.; Santino, A.; Storelli, C.; Maffia M. Resveratrol inhibits the epidermal growth factor-induced epithelial mesenchymal transition in MCF-7 cells. Cancer Lett. 2011, 310 (1), 1-8.
87. Vergara, D.; Simeone, P.; Toraldo, D.; Del Boccio, P.; Vergaro, V.; Leporatti, S.; Pieragostino, D.; Tinelli, A.; De Domenico, S.; Alberti, S.; Urbani, A.; Salzet, M.; Santino, A.; Maffia M. Resveratrol downregulates Akt/GSK and ERK signalling pathways in OVCAR-3 ovarian cancer cells. Mol. Biosyst. 2012, 8 (4), 1078-1087.